NCT03783403: A Study of CC-95251, a Monoclonal Antibody Directed Against SIRP-alpha, in Subjects With Advanced Solid and Hematologic Cancers

Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1
Drug Category: Immunotherapy, Therapeutic Antibody

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: 
Exclusions: Patients with symptomatic central nervous system involvement; Patients with prior investigational therapy directed at CD47 or SIRP-alpha

Comments are closed.

Up ↑